Loading...
•
Dec 28, 2024
Hologic Q1 2025 Earnings Report
Hologic reported its financial results for the first quarter of fiscal 2025, with revenues consistent with guidance and improved profitability.
Key Takeaways
Hologic announced financial results for the first quarter of fiscal 2025, reporting revenues of $1,021.8 million, a 0.9% increase year-over-year. GAAP diluted EPS was $0.87, while non-GAAP diluted EPS reached $1.03, hitting the high end of guidance. The company also completed the acquisition of Gynesonics, expanding its surgical portfolio.
Revenue for the first quarter of fiscal 2025 was $1,021.8 million, an increase of 0.9% (1.0% in constant currency) compared to the prior year.
Non-GAAP diluted EPS was $1.03, which was at the high end of the company's guidance range.
Diagnostics revenue increased 5.1% (5.2% in constant currency), primarily driven by higher molecular diagnostics sales.
The company repurchased 6.8 million shares for $517 million and acquired Gynesonics for approximately $350 million, broadening its surgical portfolio.
Hologic
Hologic
Hologic Revenue by Segment
Hologic Revenue by Geographic Location
Revenue by Segment
Diagnostics Revenue
CapyFin.comMolecular Diagnostics Revenue
CapyFin.comCytology & Perinatal Revenue
CapyFin.comBlood Screening Revenue
CapyFin.comBreast Health Revenue
CapyFin.comBreast Imaging Revenue
CapyFin.comInterventional Breast Solutions Revenue
CapyFin.comGYN Surgical Revenue
CapyFin.comSkeletal Health Revenue
CapyFin.comRevenue by Geographic Location
U.S. Revenue
CapyFin.comInternational Revenue
CapyFin.com Forward Guidance
Hologic is reducing its full-year revenue guidance due to currency headwinds and weakness in breast health capital sales, but maintaining non-GAAP EPS guidance based on strong profitability and capital allocation strategy.
Positive Outlook
- Maintaining full-year guidance for non-GAAP EPS.
- Strong profitability and execution of capital allocation strategy.
- Organic revenue excluding COVID-19 is expected to increase by 0.9% to 2.2% for the full year.
- Non-GAAP EPS guidance for Q2 2025 is $1.00 - $1.03.
- Full-year non-GAAP tax rate expected to be approximately 19.5%.
Challenges Ahead
- Reducing full-year revenue guidance.
- Currency headwinds impacting revenue.
- Weakness in breast health capital sales.
- Q2 2025 revenue guidance shows a reported decrease of (2.2%) to (1.3%).
- Organic revenue for Q2 2025 is expected to decrease by (2.9%) to (1.9%).
Revenue & Expenses
Visualization of income flow from segment revenue to net income